Translational Medicine Study on Circulating Tumor Cell Detection in Patients with Metastatic Breast Cancer

Translational Medicine Study on Circulating Tumor Cell Detection in Patients with Metastatic Breast Cancer

Objective: To explore the prognostic and predictive effects of circulating tumor cell (CTC) detection in patients with metastatic breast cancer (MBC). Methods: A total of 139 patients with MBC were selected to detect the peripheral blood CTC count by CellSearch system. The survival analysis was cond...

Full description

Bibliographic Details
Main Authors:	Bo SHEN, Ma-qing ZHENG, Xin-yu XU, Da WEI
Format:	Article
Language:	English
Published:	Third Party Medicine International Publishing Group Co. Limited 2015-06-01
Series:	Journal of International Translational Medicine
Subjects:	Breast cancer Circulating tumor cell Translational medicine Prognosis and prediction Progression-free survival
Online Access:	http://www.jitm.hk/EN/abstract/abstract144.shtml

Similar Items

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Chun Wang, et al.
Published: (2021-01-01)

Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies
by: Marta Tellez-Gabriel, et al.
Published: (2020-12-01)

Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker
by: Sayyed Farshid Moussavi-Harami, et al.
Published: (2014-05-01)

Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma
by: Ye X, et al.
Published: (2018-11-01)

Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
by: Maggie Banys-Paluchowski, et al.
Published: (2020-05-01)

Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine
by: Maria Panagopoulou, et al.
Published: (2021-02-01)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019-10-01)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
by: I-Chun Chen, et al.
Published: (2021-10-01)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
by: Forsythe A, et al.
Published: (2018-05-01)

Altona Prognostic Index: A New Prognostic Index for ER-Positive and Her2-Negative Breast Cancer of No Special Type
by: Anne-Sophie Wegscheider, et al.
Published: (2021-07-01)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
by: Po‐Lan Su, et al.
Published: (2019-10-01)

Meta-analysis of the studies dedicated to the predictive significance of circulating tumor DNA in pancreatic cancer
by: A. S. Popova, et al.
Published: (2020-11-01)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021-08-01)

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

Circulating Tumor Cells Undergoing the Epithelial–Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma
by: Zhang Q, et al.
Published: (2021-03-01)

Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
by: Yu N Nenahova, et al.
Published: (2016-09-01)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
by: Kümmel S, et al.
Published: (2018-11-01)

Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
by: Anna-Maria Larsson, et al.
Published: (2018-06-01)

Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters (CTC-clusters) as Predictors of Patient Outcomes
by: Clotilde Costa, et al.
Published: (2020-04-01)

Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds
by: Maxim E. Menyailo, et al.
Published: (2020-03-01)

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
by: Liu MC, et al.
Published: (2019-12-01)

Landscape of circulating tumour DNA in metastatic breast cancer
by: Andrew A. Davis, et al.
Published: (2020-08-01)

Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection
by: Eveline E. Vietsch, et al.
Published: (2019-11-01)

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer
by: Xiao-Ran Liu, et al.
Published: (2021-02-01)

Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients
by: Natalia Krawczyk, et al.
Published: (2019-11-01)

Breast cancer circulating tumor cells
by: Maria Joao Carvalho, et al.
Published: (2011-12-01)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
by: Xiuwen Guan, et al.
Published: (2019-01-01)

High Tumor Stroma Proportion is a Worse Prognostic Factor in Colorectal Cancer
by: Damir Gugić, et al.
Published: (2017-01-01)

Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
by: Katsuhiko Nakatsukasa, et al.
Published: (2021-01-01)

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
by: Fabienne Schochter, et al.
Published: (2020-04-01)

Do younger women with non-metastatic and non-inflammatory breast carcinoma have poor prognosis?
by: Rajan Balakrishnan, et al.
Published: (2004-01-01)

Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment
by: Christoph Suppan, et al.
Published: (2019-08-01)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
by: Xiaojing Xu, et al.
Published: (2020-10-01)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
by: Forsythe A, et al.
Published: (2018-05-01)

Influence of Androgen Receptor on the Prognosis of Breast Cancer
by: Ki-Tae Hwang, et al.
Published: (2020-04-01)

Circulating Tumor Cell Data: Integration with Imaging and Serum Tumor Markers for Metastatic Breast Cancer Patient Management
by: Thomas Marsland, et al.
Published: (2014-03-01)

The mode of progressive disease affects the prognosis of patients with metastatic breast cancer
by: Ryutaro Mori, et al.
Published: (2018-08-01)

Potential role of circulating tumor cell detection and monitoring in breast cancer: a review of current evidence
by: Malgorzata Banys-Paluchowski, et al.
Published: (2016-12-01)

Correlation between Androgen Receptor Expression and Immunohistochemistry Type as Prognostic Factors in a Cohort of Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study
by: Irina Niță, et al.
Published: (2021-03-01)

Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle
by: Stefan Stefanovic, et al.
Published: (2020-06-01)